



**What:** Finance/Audit Committee Meeting  
**Date & Time:** Thursday, September 19, 2019; 3:00-4:00 p.m. (PDT)  
**Location:** In-person at Cigna- 701 5<sup>th</sup> Ave., Suite 4900 Seattle, WA  
**Conference Line:** (267) 930-4000; Conference ID: 103063718#

Notice: Meeting may be recorded for the benefit of the minute-taker. The WVA intends to delete the recording after the minutes of the meeting are approved.

Approx. Time	Topic / <b>Anticipated Action</b>	Presented by:
3:00-3:05 p.m.	1. Welcome & Introductions a. Notification of Recording	J. Sobeck J. Zell
3:05-3:10 p.m.	2. Calendar Consent Items * a. <b>Finance Committee Minutes - May 23, 2019</b>	J. Sobeck
3:10-3:25 p.m.	3. Financial Update a. Investments * b. Overview * c. Reserve Target - Grid Reductions	P. Sidwell P. Smith
3:25-3:45 p.m.	4. 2018-2019 Audited Financials * a. Overview b. Questions & Comments c. <b>Vote to Recommend Publication of the 2018/19 Audited Financials</b>	A. Gilbert
3:45-3:50 p.m.	5. Other Matters from Committee Members	Any
3:50-4:00 p.m.	6. Executive Session (KidsVax <sup>®</sup> and public excluded)	J. Sobeck
4:00 p.m.	7. Closing	J. Sobeck



**Washington Vaccine Association  
Finance Committee Meeting  
May 23, 2019, 3:00-4:00 p.m. (PDT)**

**I. Attendance.** The following individuals participated by telephone:

Directors

John Sobeck, MD, Chair, Cigna  
Jason Farber, Esq., Davis Wright  
Tremaine, LLC

Executive Director

Julia Zell, Esq., WVA ED

KidsVax®

Fred Potter, Managing Member  
Peter Smith, Financial Analyst  
Norman Roberge, Accountant  
Claire Roberge, Controller  
Terry Mills, Executive Assistant

Others

Polly Sidwell, Morgan Stanley

**II. Summary of Actions Taken and/or Recommended**

**A. Actions Taken (votes adopted)**

1. To engage CliftonLarsonAllen to prepare the 2018/19 WVA Audit.

**III. Meeting Minutes**

At 3:00 p.m., a quorum having been established, Chairman John Sobeck called the meeting to order. Chairman Sobeck announced that the meeting was being recorded for the benefit of the minute-taker and would be deleted following the final approval of the minutes.

Administrative Business

Mr. Farber reported that he had received many emails from the KidsVax® (KV) notification system. He asked Ms. Zell if she would ask someone to explore the problem. Ms. Zell explained that there have been some issues with the WVA notification system and KV is working with SolutionWorx to correct the problem as quickly as possible.

Financial Update

Ms. Sidwell presented an investment update. She reported that there is almost \$45MM in the Bond Portfolio at Morgan Stanley (MS). The account has earned almost \$500,000 in just under seven months. Approximately \$36MM of the \$45MM are in the Reserves Portfolio. Since its inception in early October 2018 there has been a couple of different transfers that have built it up to the \$36MM. The market value now is just under \$36.7MM, with a little over \$515,000 in income that has been earned from the bonds as they have come due. There is also approximately \$130,000 in earnings that are the combination of the income that has paid out and either the appreciation or depreciation of the bonds. Since inception, the overall performance is up about 2.34% in the Reserves Portfolio. Interest rates have moved down slightly in the 3-5-year range, creating some gains on the overall portfolio, which is governed by the Investment Policy Statement. MS's duration is currently at a 1½ years. Overall the expected duration should be around 1½-2 years going forward. There is a combination of Treasury and Agency Bonds that is approximately 30% of the portfolio, with approximately 23% FDIC insured CDs and 47% in Corporate Bonds. Ms. Sidwell assured the Committee that MS pays impeccable attention to following all the parameters outlined in the Investment Policy. MS is projecting the earnings over the next year to be about \$1,059,000, based on the decision the Committee made to break into this sort of portfolio to earn the income. The bar graphs on page 2 show year-by-year how MS is stacked up with the bond maturity and the last page lists each of the individual bonds. At Ms. Sidwell's initial presentation to the Committee, several members noticed that the list included a couple of Pharma or Healthcare names, so MS is staying away from those bonds. The Cash Operating Account consists of transferring liquidity funds that are at KeyBank (KB) over to MS where they hold them in the ultrashort institutional liquidity fund that has daily liquidity.

1 That fund is yielding about 2.38%. To date, approximately \$8.5MM has been deposited there and the earnings so far  
2 have been about \$38,200.

3  
4 Ms. Zell reported that Peter Smith and Claire Roberge are ready to move another \$3MM from WVA's Liquidity  
5 Account into the Bond Portfolio. Ms. Zell wanted Finance Committee approval prior to moving the funds. Ms.  
6 Sidwell relayed to the Committee that there will be approximately \$5.5MM in bonds coming due before the end of  
7 the year. Mr. Smith indicated that he feels moving the \$3MM is prudent at this time. Ms. Zell authorized Ms. Sidwell  
8 to make that transfer into the Bond Portfolio.

9  
10 Mr. Smith provided an overview of the WVA's fiscal position showing a cashflow overview of the last several months.  
11 There is \$45-46MM in investment accounts at MS and an additional \$3.6MM in KB, bringing the total to \$47-48MM  
12 cash assets currently. A high-level overview on page 3 shows the metrics that Ms. Zell normally reports in her ED  
13 summary. The Collections Report goes into some of the detail of the monthly action of different items coming in and  
14 going out. The compiled internal financial statements show \$58MM of current assets, including prepaids on the  
15 balance sheet, as well as the Statement of Activities for the 10 months ending April 30. WVA is currently in the  
16 middle of a grid update cycle, so those changes will be implemented over the next several months and the cashflow  
17 following that.

18  
19 Ms. Zell reported on a compliance issue with HMA which became public because it has been ongoing for several  
20 years. They have gone back and reprocessed thousands of claims where they had improperly paid the provider on  
21 certain vaccine codes rather than paying the WVA. After going through, it was determined that over \$105,000 was  
22 due to WVA.

#### 23 24 Annual Audit

25 CliftonLarsonAllen, who has traditionally been the WVA auditor, was asked to put together an engagement letter. It  
26 is similar in structure and within the same standards as previous years, but they switch actual auditors. Ms. Zell  
27 indicated there are a few different requests WVA would make now that there is an employee and a payroll system.  
28 There are some additions to the audited financials, but it is straightforward. Ms. Zell asked if Mr. Smith had any  
29 additional comments regarding the reasonableness of the audit cost this year and/or on its substantive content. Mr.  
30 Smith indicated that it looks good and they continue to do a great job for the WVA. Mrs. Roberge also indicated it is  
31 going very well and would like to continue using their services if possible.

32  
33 Upon motion duly made and seconded, it was unanimously

34  
35 **VOTED:** To engage CliftonLarsonAllen to prepare the 2018/19 WVA Audit.

36  
37 The audit will be prepared over the summer and should be ready for the Annual Report and the Board's review for  
38 publication in November. There is an Audit Meeting prior to that when the audit will be reviewed with the auditor  
39 present.

40  
41 Chairman Sobeck indicated that if the WVA continues to accumulate cash faster than expected, even though the WVA  
42 absorbed the grid increase and did the decrease, the Board will want to think about if other larger increases will need  
43 to be done and start planning for that. Ms. Zell reported that the KV team has been working hard on generating  
44 updated internal financials that will help with the budget tracking for the year and the Annual Budget. KV sent Ms.  
45 Zell a draft, but will have the Annual Operations Budget in time for the Executive Committee Meeting in a few weeks.  
46 Mr. Potter reported that KV identified one of the reasons for the higher cash accumulation. Ms. Zell will communicate  
47 this information to the Finance Committee confidentially.

#### 48 49 Closing

50  
51 **VOTED:** To end the meeting at approximately 3:31 p.m. (PDT).



UWVA Cash Flow Projection Model  
As of September 10, 2019

Amounts in **BOLD** are actuals.

Month	Projected Net Cash Receipts	Projected DOH Reimb	Flu / CDC Advance	Admin Exp / Other	Interest income / expense	To/from Interest Bearing	Net Cash Change	Cash Balance (a)	LOC / Interest Bearing (b)	Net Liquidity (a + b)	Notes
Jul-16	5,626,346	(4,444,198)	(1,263,808)	(123,581)	(29,350)	-	(234,592)	4,924,570	(10,000,000)	(5,075,430)	
Aug-16	7,739,005	(5,615,932)	-	(77,425)	(27,986)	(1,000,000)	1,017,663	5,942,233	(9,000,000)	(3,057,767)	
Sep-16	9,041,533	(5,546,402)	(2,507,129)	(113,138)	(28,064)	(2,000,000)	(1,153,201)	4,789,032	(7,000,000)	(2,210,968)	< Adjust Rates as of 7/1 to 130% of current C
Oct-16	7,482,696	(4,748,545)	-	(79,988)	(24,742)	(2,000,000)	629,420	5,418,452	(5,000,000)	418,452	
Nov-16	8,855,104	(4,457,024)	-	(91,560)	(19,783)	(2,500,000)	1,786,737	7,205,189	(2,500,000)	4,705,189	
Dec-16	6,135,734	(5,450,704)	-	(66,989)	(8,982)	(2,500,000)	(1,890,941)	5,314,248	-	5,314,248	< LOC Paid off by 12/31
Jan-17	5,339,947	(5,318,030)	-	(90,691)	-	-	(68,774)	5,245,474	-	5,245,474	
Feb-17	5,824,066	(4,226,052)	-	(97,429)	-	-	1,500,584	6,746,058	-	6,746,058	
Mar-17	6,844,922	(5,433,956)	-	(80,760)	-	-	1,330,207	8,076,265	-	8,076,265	
Apr-17	5,261,908	(5,334,158)	-	(57,425)	-	-	(129,674)	7,946,590	-	7,946,590	
May-17	5,811,994	(5,286,633)	-	(72,018)	-	-	453,342	8,399,932	-	8,399,932	
Jun-17	6,302,549	(5,014,254)	-	(105,930)	-	-	1,182,365	9,582,298	-	9,582,298	
Jul-17	5,608,570	(7,562,171)	-	(113,526)	-	-	(2,067,127)	7,515,171	-	7,515,171	
Aug-17	7,828,758	(7,225,017)	-	(93,327)	-	-	510,414	8,025,584	-	8,025,584	
Sep-17	8,086,399	(5,249,429)	(3,638,937)	(78,530)	-	-	(880,497)	7,145,088	-	7,145,088	
Oct-17	7,116,156	(5,437,731)	-	(71,765)	-	-	1,606,659	8,751,747	-	8,751,747	
Nov-17	8,215,489	(4,210,946)	-	(71,156)	-	-	3,933,387	12,685,134	-	12,685,134	
Dec-17	6,422,096	(4,118,584)	-	(205,290)	-	-	2,098,222	14,783,356	-	14,783,356	
Jan-18	5,886,214	(4,236,192)	-	(127,046)	-	-	1,522,975	16,306,331	-	16,306,331	
Feb-18	6,033,821	(3,432,432)	-	(95,751)	-	-	2,505,638	18,811,969	-	18,811,969	
Mar-18	18,263,903	(4,301,740)	-	(650,899)	-	-	13,311,264	32,123,233	-	32,123,233	< Includes TRICARE payment
Apr-18	5,411,000	(5,057,707)	-	(39,140)	-	-	314,154	32,437,387	-	32,437,387	
May-18	6,186,270	(6,006,860)	-	(63,806)	-	-	115,604	32,552,991	-	32,552,991	
Jun-18	5,588,325	(3,861,593)	-	(149,629)	-	-	1,577,103	34,130,094	-	34,130,094	
Jul-18	6,839,965	(6,247,878)	-	(141,226)	-	-	450,861	34,580,954	-	34,580,954	
Aug-18	7,848,181	(7,834,032)	-	(111,925)	-	-	(97,776)	34,483,178	-	34,483,178	
Sep-18	7,527,848	(5,206,974)	(3,720,022)	(99,018)	13,211	(25,000,000)	(26,484,955)	7,998,223	25,000,000	32,998,223	< Grid Rates reduced by 1% on July 1
Oct-18	7,638,131	(4,685,595)	-	(99,350)	(4,155)	-	2,849,030	10,847,253	25,000,000	35,847,253	
Nov-18	8,546,543	(4,529,870)	-	(94,069)	64,673	(64,673)	3,922,605	14,769,858	25,064,673	39,834,531	
Dec-18	7,005,729	(4,103,869)	-	(108,485)	134,286	(134,286)	2,793,376	17,563,233	25,198,959	42,762,193	< DOH Increases Indirect rate to 4%
Jan-19	6,342,631	(4,716,256)	-	(119,502)	153,971	(16,398,889)	(14,738,045)	2,825,189	41,597,848	44,423,037	< Includes 5.75% CDC rate increase
Feb-19	5,156,707	(3,000,686)	-	(75,133)	60,275	-	2,141,163	4,966,352	41,597,848	46,564,200	
Mar-19	6,490,515	(4,782,115)	-	(16,901)	199,600	-	1,891,100	6,857,451	41,597,848	48,455,300	
Apr-19	6,055,530	(4,190,976)	-	(115,703)	112,494	(4,000,000)	(2,138,655)	4,718,796	45,597,848	50,316,645	
May-19	6,692,141	(6,259,643)	-	(89,126)	176,102	275,149	794,623	5,513,419	45,322,699	50,836,119	
Jun-19	5,945,345	(6,462,245)	-	(84,996)	243,748	-	(358,148)	4,911,523	45,566,447	50,477,971	< Grid Rates reduced by 2% on July 1
Jul-19	6,606,543	(7,092,489)	-	(73,203)	61,527	2,000,000	1,502,378	6,352,374	43,627,974	49,980,349	
Aug-19	8,180,983	(7,219,840)	-	(14,586)	228,015	-	1,174,572	7,298,932	43,855,989	51,154,921	

WVA Cash Flow Projection Model  
As of September 10, 2019

Amounts in **BOLD** are actuals.

Month	Projected Net Cash Receipts	Projected DOH Reimb	Flu / CDC Advance	Admin Exp / Other	Interest income / expense	To/from Interest Bearing	Net Cash Change	Cash Balance (a)	LOC / Interest Bearing (b)	Net Liquidity (a + b)	Notes
Sep-19	6,516,365	(5,372,689)	(3,561,582)	(82,506)	113,295	2,000,000	(387,117)	6,798,520	41,969,284	48,767,804	
Oct-19	5,197,129	(5,204,875)		(82,506)	108,421		18,169	6,708,268	42,077,704	48,785,972	
Nov-19	4,891,011	(3,975,224)		(82,506)	108,701		941,982	7,541,549	42,186,405	49,727,954	
Dec-19	4,005,568	(4,212,533)		(82,506)	108,982	(1,000,000)	(1,180,489)	6,252,079	43,295,387	49,547,465	
Jan-20	4,046,277	(4,922,710)		(82,506)	111,846	1,000,000	152,907	6,293,140	42,407,233	48,700,373	< Includes 1% grid decrease at Jan 1
Feb-20	4,501,487	(4,130,226)		(82,506)	109,552		398,308	6,581,895	42,516,785	49,098,680	
Mar-20	4,150,169	(5,803,643)		(82,506)	109,835		(1,626,144)	4,845,916	42,626,620	47,472,536	
Apr-20	5,163,882	(4,624,470)		(82,506)	110,119		567,024	5,302,821	42,736,739	48,039,560	
May-20	4,418,372	(6,062,241)		(82,506)	110,403	2,000,000	384,029	5,576,447	40,847,142	46,423,589	< Includes estimated 4% CDC rate increase
Jun-20	5,354,508	(6,720,564)		(82,506)	105,522	1,000,000	(343,040)	5,127,885	39,952,664	45,080,548	
Jul-20	5,983,585	(7,395,596)		(82,506)	103,211	2,000,000	608,695	5,633,368	38,055,875	43,689,243	
Aug-20	6,511,508	(7,529,807)		(82,506)	98,311	1,000,000	(2,493)	5,532,564	37,154,186	42,686,750	
Sep-20	6,495,841	(5,589,213)	(3,571,287)	(82,506)	95,982	3,000,000	348,816	5,785,398	34,250,168	40,035,566	
Oct-20	5,168,077	(5,412,527)		(82,506)	88,480		(238,477)	5,458,442	34,338,647	39,797,089	
Nov-20	4,773,093	(4,133,260)		(82,506)	88,708	(1,000,000)	(353,965)	5,015,769	35,427,355	40,443,124	
Dec-20	3,906,750	(4,381,458)		(82,506)	91,521	1,000,000	534,306	5,458,554	34,518,876	39,977,430	
Jan-21	4,030,011	(5,121,050)		(82,506)	89,174	1,000,000	(84,371)	5,285,009	33,608,050	38,893,059	
Feb-21	4,485,186	(4,295,551)		(82,506)	86,821		193,950	5,392,138	33,694,871	39,087,009	
Mar-21	4,133,699	(6,036,832)		(82,506)	87,045	1,000,000	(898,594)	4,406,500	32,781,916	37,188,415	
Apr-21	5,146,168	(4,808,835)		(82,506)	84,687	1,000,000	1,339,514	5,661,327	31,866,602	37,527,930	
May-21	4,477,141	(6,303,975)		(82,506)	82,322	2,000,000	172,982	5,751,987	29,948,924	35,700,912	< Includes estimated 4% CDC rate increase
Jun-21	5,427,734	(6,989,386)		(82,506)	77,368	1,000,000	(566,791)	5,107,829	29,026,292	34,134,121	



UWVA Cash Flow Projection Model  
As of September 10, 2019

Amounts in **BOLD** are actuals.

Month	Projected Net Cash Receipts	Projected DOH Reimb	Flu / CDC Advance	Admin Exp / Other	Interest income / expense	To/from Interest Bearing	Net Cash Change	Cash Balance (a)	LOC / Interest Bearing (b)	Net Liquidity (a + b)	Notes
Jul-16	5,626,346	(4,444,198)	(1,263,808)	(123,581)	(29,350)	-	(234,592)	4,924,570	(10,000,000)	(5,075,430)	
Aug-16	7,739,005	(5,615,932)	-	(77,425)	(27,986)	(1,000,000)	1,017,663	5,942,233	(9,000,000)	(3,057,767)	
Sep-16	9,041,533	(5,546,402)	(2,507,129)	(113,138)	(28,064)	(2,000,000)	(1,153,201)	4,789,032	(7,000,000)	(2,210,968)	< Adjust Rates as of 7/1 to 130% of current C
Oct-16	7,482,696	(4,748,545)	-	(79,988)	(24,742)	(2,000,000)	629,420	5,418,452	(5,000,000)	418,452	
Nov-16	8,855,104	(4,457,024)	-	(91,560)	(19,783)	(2,500,000)	1,786,737	7,205,189	(2,500,000)	4,705,189	
Dec-16	6,135,734	(5,450,704)	-	(66,989)	(8,982)	(2,500,000)	(1,890,941)	5,314,248	-	5,314,248	< LOC Paid off by 12/31
Jan-17	5,339,947	(5,318,030)	-	(90,691)	-	-	(68,774)	5,245,474	-	5,245,474	
Feb-17	5,824,066	(4,226,052)	-	(97,429)	-	-	1,500,584	6,746,058	-	6,746,058	
Mar-17	6,844,922	(5,433,956)	-	(80,760)	-	-	1,330,207	8,076,265	-	8,076,265	
Apr-17	5,261,908	(5,334,158)	-	(57,425)	-	-	(129,674)	7,946,590	-	7,946,590	
May-17	5,811,994	(5,286,633)	-	(72,018)	-	-	453,342	8,399,932	-	8,399,932	
Jun-17	6,302,549	(5,014,254)	-	(105,930)	-	-	1,182,365	9,582,298	-	9,582,298	
Jul-17	5,608,570	(7,562,171)	-	(113,526)	-	-	(2,067,127)	7,515,171	-	7,515,171	
Aug-17	7,828,758	(7,225,017)	-	(93,327)	-	-	510,414	8,025,584	-	8,025,584	
Sep-17	8,086,399	(5,249,429)	(3,638,937)	(78,530)	-	-	(880,497)	7,145,088	-	7,145,088	
Oct-17	7,116,156	(5,437,731)	-	(71,765)	-	-	1,606,659	8,751,747	-	8,751,747	
Nov-17	8,215,489	(4,210,946)	-	(71,156)	-	-	3,933,387	12,685,134	-	12,685,134	
Dec-17	6,422,096	(4,118,584)	-	(205,290)	-	-	2,098,222	14,783,356	-	14,783,356	
Jan-18	5,886,214	(4,236,192)	-	(127,046)	-	-	1,522,975	16,306,331	-	16,306,331	
Feb-18	6,033,821	(3,432,432)	-	(95,751)	-	-	2,505,638	18,811,969	-	18,811,969	
Mar-18	18,263,903	(4,301,740)	-	(650,899)	-	-	13,311,264	32,123,233	-	32,123,233	< Includes TRICARE payment
Apr-18	5,411,000	(5,057,707)	-	(39,140)	-	-	314,154	32,437,387	-	32,437,387	
May-18	6,186,270	(6,006,860)	-	(63,806)	-	-	115,604	32,552,991	-	32,552,991	
Jun-18	5,588,325	(3,861,593)	-	(149,629)	-	-	1,577,103	34,130,094	-	34,130,094	
Jul-18	6,839,965	(6,247,878)	-	(141,226)	-	-	450,861	34,580,954	-	34,580,954	
Aug-18	7,848,181	(7,834,032)	-	(111,925)	-	-	(97,776)	34,483,178	-	34,483,178	
Sep-18	7,527,848	(5,206,974)	(3,720,022)	(99,018)	13,211	(25,000,000)	(26,484,955)	7,998,223	25,000,000	32,998,223	< Grid Rates reduced by 1% on July 1
Oct-18	7,638,131	(4,685,595)	-	(99,350)	(4,155)	-	2,849,030	10,847,253	25,000,000	35,847,253	
Nov-18	8,546,543	(4,529,870)	-	(94,069)	64,673	(64,673)	3,922,605	14,769,858	25,064,673	39,834,531	
Dec-18	7,005,729	(4,103,869)	-	(108,485)	134,286	(134,286)	2,793,376	17,563,233	25,198,959	42,762,193	
Jan-19	6,342,631	(4,716,256)	-	(119,502)	153,971	(16,398,889)	(14,738,045)	2,825,189	41,597,848	44,423,037	
Feb-19	5,156,707	(3,000,686)	-	(75,133)	60,275	-	2,141,163	4,966,352	41,597,848	46,564,200	
Mar-19	6,490,515	(4,782,115)	-	(16,901)	199,600	-	1,891,100	6,857,451	41,597,848	48,455,300	
Apr-19	6,055,530	(4,190,976)	-	(115,703)	112,494	(4,000,000)	(2,138,655)	4,718,796	45,597,848	50,316,645	< DOH Increases Indirect rate to 4%
May-19	6,692,141	(6,259,643)	-	(89,126)	176,102	275,149	794,623	5,513,419	45,322,699	50,836,119	< Includes 5.75% CDC rate increase
Jun-19	5,945,345	(6,462,245)	-	(84,996)	243,748	-	(358,148)	4,911,523	45,566,447	50,477,971	
Jul-19	6,606,543	(7,092,489)	-	(73,203)	61,527	2,000,000	1,502,378	6,352,374	43,627,974	49,980,349	< Grid Rates reduced by 2% on July 1
Aug-19	8,180,983	(7,219,840)	-	(14,586)	228,015	-	1,174,572	7,298,932	43,855,989	51,154,921	

WVA Cash Flow Projection Model  
As of September 10, 2019

Amounts in **BOLD** are actuals.

Month	Projected Net Cash Receipts	Projected DOH Reimb	Flu / CDC Advance	Admin Exp / Other	Interest income / expense	To/from Interest Bearing	Net Cash Change	Cash Balance (a)	LOC / Interest Bearing (b)	Net Liquidity (a + b)	Notes
Sep-19	6,516,365	(5,372,689)	(3,561,582)	(82,506)	113,295	2,000,000	(387,117)	6,798,520	41,969,284	48,767,804	
Oct-19	5,197,129	(5,204,875)		(82,506)	108,421		18,169	6,708,268	42,077,704	48,785,972	
Nov-19	4,891,011	(3,975,224)		(82,506)	108,701		941,982	7,541,549	42,186,405	49,727,954	
Dec-19	4,005,568	(4,212,533)		(82,506)	108,982	(1,000,000)	(1,180,489)	6,252,079	43,295,387	49,547,465	
Jan-20	3,961,980	(4,922,710)		(82,506)	111,846	1,000,000	68,610	6,208,842	42,407,233	48,616,075	< Includes 2% grid decrease at Jan 1
Feb-20	4,407,706	(4,130,226)		(82,506)	109,552		304,527	6,403,817	42,516,785	48,920,602	
Mar-20	4,063,708	(5,803,643)		(82,506)	109,835		(1,712,606)	4,581,376	42,626,620	47,207,996	
Apr-20	5,056,301	(4,624,470)		(82,506)	110,119		459,443	4,930,700	42,736,739	47,667,439	
May-20	4,326,323	(6,062,241)		(82,506)	110,403	2,000,000	291,979	5,112,276	40,847,142	45,959,418	< Includes estimated 4% CDC rate increase
Jun-20	5,242,955	(6,720,564)		(82,506)	105,522	2,000,000	545,407	5,552,162	38,952,664	44,504,826	
Jul-20	5,858,927	(7,395,596)		(82,506)	100,628	1,000,000	(518,547)	4,932,987	38,053,292	42,986,279	
Aug-20	6,375,852	(7,529,807)		(82,506)	98,304	2,000,000	861,844	5,696,527	36,151,596	41,848,122	
Sep-20	6,360,511	(5,589,213)	(3,571,287)	(82,506)	93,392	3,000,000	210,896	5,814,031	33,244,988	39,059,019	
Oct-20	5,060,409	(5,412,527)		(82,506)	85,883		(348,742)	5,379,406	33,330,870	38,710,277	
Nov-20	4,673,654	(4,133,260)		(82,506)	86,105		543,992	5,837,294	33,416,975	39,254,269	
Dec-20	3,825,359	(4,381,458)		(82,506)	86,327	1,000,000	447,722	6,198,689	32,503,302	38,701,991	
Jan-21	3,946,052	(5,121,050)		(82,506)	83,967	1,000,000	(173,537)	5,941,185	31,587,269	37,528,454	
Feb-21	4,391,745	(4,295,551)		(82,506)	81,600		95,288	5,954,873	31,668,870	37,623,743	
Mar-21	4,047,580	(6,036,832)		(82,506)	81,811	2,000,000	10,054	5,883,115	29,750,681	35,633,796	
Apr-21	5,038,956	(4,808,835)		(82,506)	76,856		224,472	6,030,731	29,827,537	35,858,268	
May-21	4,489,080	(6,303,975)		(82,506)	77,054	1,000,000	(820,346)	5,133,330	28,904,591	34,037,922	< Includes estimated 4% CDC rate increase
Jun-21	5,442,208	(6,989,386)		(82,506)	74,670	2,000,000	444,985	5,503,646	26,979,262	32,482,907	

**WASHINGTON VACCINE ASSOCIATION**  
**FINANCIAL STATEMENTS**  
**YEARS ENDED JUNE 30, 2019 AND 2018**



**WASHINGTON VACCINE ASSOCIATION  
TABLE OF CONTENTS  
YEARS ENDED JUNE 30, 2019 AND 2018**

<b>INDEPENDENT AUDITORS' REPORT</b>	<b>1</b>
<b>FINANCIAL STATEMENTS</b>	
<b>STATEMENTS OF FINANCIAL POSITION</b>	<b>3</b>
<b>STATEMENTS OF ACTIVITIES</b>	<b>4</b>
<b>STATEMENTS OF CASH FLOWS</b>	<b>6</b>
<b>NOTES TO FINANCIAL STATEMENTS</b>	<b>7</b>



CliftonLarsonAllen LLP  
CLAconnect.com

## INDEPENDENT AUDITORS' REPORT

Board of Directors  
Washington Vaccine Association  
Seattle, Washington

We have audited the accompanying financial statements of Washington Vaccine Association (a nonprofit organization), which comprise the statements of financial position as of June 30, 2019 and 2018, and the related statements of activities and cash flows for the years then ended, and the related notes to the financial statements.

### ***Management's Responsibility for the Financial Statements***

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

### ***Auditors' Responsibility***

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Board of Directors  
Washington Vaccine Association

***Opinion***

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Washington Vaccine Association as of June 30, 2019 and 2018, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

**CliftonLarsonAllen LLP**

Bellevue, Washington  
REPORT DATE

**WASHINGTON VACCINE ASSOCIATION  
STATEMENTS OF FINANCIAL POSITION  
JUNE 30, 2019 AND 2018**

	2019	2018
<b>ASSETS</b>		
<b>CURRENT ASSETS</b>		
Cash and Cash Equivalents	\$ 4,921,995	\$ 34,120,976
Estimated Collectible Assessments	5,345,981	6,355,445
Prepaid Vaccines to Washington Department of Health	6,462,245	3,861,593
Total Current Assets	16,730,221	44,338,014
<b>INVESTMENTS</b>	45,555,976	9,118
Total Assets	\$ 62,286,197	\$ 44,347,132
<b>LIABILITIES AND NET ASSETS WITHOUT RESTRICTIONS</b>		
<b>CURRENT LIABILITIES</b>		
Accounts Payable	\$ 22,708	\$ 97,928
<b>ASSESSMENTS COLLECTED IN EXCESS OF VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES</b>		
	62,263,489	44,249,204
Total Liabilities	62,286,197	44,347,132
<b>NET ASSETS WITHOUT RESTRICTIONS</b>	-	-
Total Liabilities and Net Assets Without Restrictions	\$ 62,286,197	\$ 44,347,132

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION  
STATEMENT OF ACTIVITIES  
YEAR ENDED JUNE 30, 2019**

	Administrative Activities	Vaccine Funding Activities	Total
<b>CHANGE IN NET ASSETS WITHOUT RESTRICTION</b>			
Assessment Activity:			
Assessments	\$ 11,431,254	\$ 69,682,340	\$ 81,113,594
Vaccine Replenishments	-	(63,139,509)	(63,139,509)
Tricare Expense Offset	191,858.00	-	191,858
Net Assessment Activity	<u>11,623,112</u>	<u>6,542,831</u>	<u>18,165,943</u>
Investment Income:			
Interest and Dividends	785,846	-	785,846
Realized Gain on Investments	6,404	-	6,404
Unrealized Appreciation of Fair Value	435,229	-	435,229
Total Investment Income	<u>1,227,479</u>	<u>-</u>	<u>1,227,479</u>
Less: Investment Expenses	<u>(68,582)</u>	<u>-</u>	<u>(68,582)</u>
Net Investment Income	1,158,897	-	1,158,897
Expenses:			
Administrative:			
Payroll	213,265	-	213,265
Third-Party Administrative Services	452,808	-	452,808
Special Projects Services	419,360	-	419,360
Legal and Accounting	95,917	-	95,917
Office Expenses	85,300	-	85,300
Other	43,905	-	43,905
Total Expenses	<u>1,310,555</u>	<u>-</u>	<u>1,310,555</u>
Total Change in Net Assets Without Restrictions	11,471,454	6,542,831	18,014,285
<b>VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES IN EXCESS OF ASSESSMENTS COLLECTED</b>	<u>(11,471,454)</u>	<u>(6,542,831)</u>	<u>(18,014,285)</u>
<b>CHANGES IN NET ASSETS WITHOUT RESTRICTIONS</b>	-	-	-
Net Assets Without Restrictions - Beginning of Year	<u>-</u>	<u>-</u>	<u>-</u>
<b>NET ASSETS WITHOUT RESTRICTIONS - END OF YEAR</b>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION  
STATEMENT OF ACTIVITIES  
YEAR ENDED JUNE 30, 2018**

	Administrative Activities	Vaccine Funding Activities	Total
<b>CHANGE IN NET ASSETS WITHOUT RESTRICTIONS</b>			
Assessment Activity:			
Assessments	\$ 13,623,126	\$ 73,639,011	\$ 87,262,137
Vaccine Replenishments	-	(65,491,991)	(65,491,991)
Net Assessment Activity	13,623,126	8,147,020	21,770,146
Investment Income:			
Interest Income on Assessments	51,903	-	51,903
Expenses:			
Administrative:			
Third-Party Administrative Services	775,292	-	775,292
Special Projects Services	651,442	-	651,442
Legal and Accounting	306,813	-	306,813
Office	41,623	-	41,623
Other	46,692	-	46,692
Total Expenses	1,821,862	-	1,821,862
Total Change in Net Assets Without Restrictions	11,853,167	8,147,020	20,000,187
<b>VACCINE FUNDING AND ADMINISTRATIVE ACTIVITIES IN EXCESS OF ASSESSMENTS COLLECTED</b>	<u>(11,853,167)</u>	<u>(8,147,020)</u>	<u>(20,000,187)</u>
<b>CHANGES IN NET ASSETS WITHOUT RESTRICTIONS</b>	-	-	-
Net Assets Without Restrictions - Beginning of Year	-	-	-
<b>NET ASSETS WITHOUT RESTRICTIONS - END OF YEAR</b>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ -</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION  
STATEMENTS OF CASH FLOWS  
YEARS ENDED JUNE 30, 2019 AND 2018**

	<u>2019</u>	<u>2018</u>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Assessments Collected	\$ 82,314,916	\$ 90,615,562
Cash Remittances to Washington Department of Health for Vaccines	(65,740,161)	(64,339,330)
Administrative Expenses Paid	(1,385,776)	(1,780,094)
Cash Received from Interest and Dividend Income	785,846	51,903
Cash Paid for Investment Expenses	<u>(68,582)</u>	<u>-</u>
Net Cash Provided by Operating Activities	15,906,243	24,548,041
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Investment Purchases	(103,283,388)	(9,118)
Proceeds from Investment Sales	<u>58,178,164</u>	<u>-</u>
Net Cash Used by Investing Activities	(45,105,224)	(9,118)
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	(29,198,981)	24,538,923
Cash and Cash Equivalents - Beginning of Year	<u>34,120,976</u>	<u>9,582,053</u>
<b>CASH AND CASH EQUIVALENTS - END OF YEAR</b>	<u>\$ 4,921,995</u>	<u>\$ 34,120,976</u>
<b>RECONCILIATION OF CHANGES IN NET ASSETS TO NET CASH PROVIDED BY OPERATING ACTIVITIES</b>		
Changes in Net Assets	\$ -	\$ -
Adjustments to Reconcile Changes in Net Assets to Net Cash Provided by Operating Activities:		
Realized Gain on Investments	(6,404)	
Unrealized Appreciation of Fair Value	(435,229)	
(Increase) Decrease in:		
Estimated Collectible Assessments	1,009,463	3,353,425
Prepaid Vaccines to Washington Department of Health	(2,600,652)	1,152,661
Increase (Decrease) in:		
Accounts Payable	(75,220)	41,769
Assessments Collected in Excess of Vaccine Funding and Administrative Activities	<u>18,014,285</u>	<u>20,000,186</u>
Net Cash Provided by Operating Activities	<u>\$ 15,906,243</u>	<u>\$ 24,548,041</u>

See accompanying Notes to Financial Statements.

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 1 NATURE OF ORGANIZATION**

**Organization and Operations**

Since 1990, Washington State has maintained a Universal Childhood Vaccine Program, providing vaccines to all children under age 19. Together with state and federal funding, Washington's program has advanced the widely recognized benefits of universal childhood vaccination. Faced with a scheduled end to state funding in 2010, the Washington State legislature established the Washington Vaccine Association (the Association) and mandated the creation of a universal vaccine purchase account to be able to continue providing state-supplied vaccines to privately-insured children. This legislation was adopted after a year of study by and with broad support from the Washington healthcare community.

The Association is a special purpose nonprofit corporation formed on April 1, 2010, to support the state government in developing and administering a new method for collecting funds to support the Universal Childhood Vaccine Program. The Washington legislature created the Association through the Washington Vaccine Association Act, now codified in RCW 70.290.010 – .900.

The Association's members are comprised of all health insurance carriers issuing or renewing health benefit plans in Washington State, and all third-party administrators (TPAs) conducting business on behalf of residents of Washington State or Washington health care plans.

The Association's primary purpose is to collect funds through mandatory assessments paid by its members. Fund transfers are made to the state of Washington Department of Health (DOH) on a just-in-time basis for the on-going pre-purchase of vaccines. The vaccines are to be administered to children in the state of Washington who are under the age of 19 and who are not eligible for federally or state funded vaccines through existing programs.

The Association is operated under a Plan of Operation adopted by the board of directors as required by RCW 70.920.030 (5)(b). The Association's governance documents are available at the Association's website: [www.wavaccine.org](http://www.wavaccine.org).

**Termination of the Association**

The Association's board may vote to recommend termination of the Association if it finds that the original intent of its formation and operation has not been achieved. The Association's board must provide notice of the recommendation to the relevant policy and fiscal committees of the Washington State legislature within 30 days of the vote being taken by the Association's board. If the legislature has not acted by the last day of legislative session to reject the board's recommendation, the board may vote to permanently dissolve the Association.

In the event of a voluntary or involuntary dissolution of the Association, funds remaining in the Universal Purchase Vaccine Account (UVPVA) created in RCW 43.70.720 must be returned to members in proportion to their previous year's contribution, from any balance remaining.



**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of Accounting**

The financial statements of the Association have been prepared in accordance with the provisions of accounting standards generally accepted in the United States of America. Under those standards, net assets and revenues, expenses, gains, and losses are classified based on the existence or absence of donor-imposed restrictions. The Association's net assets do not contain restrictions as of June 30, 2019 and 2018.

**Adoption of New Accounting Standard**

On August 18, 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2016-14, *Not-for-Profit Entities (Topic 958) – Presentation of Financial Statements of Not-for-Profit Entities*. The update addresses the complexity and understandability of net asset classification, deficiencies in information about liquidity and availability of resources, and the lack of consistency in the type of information provided about expenses and investment return. The Association has implemented ASU 2016-14 and has adjusted the presentation in these financial statements accordingly. The ASU has been applied retrospectively to all periods presented which resulted in no change to the total previously reported net assets.

**Concentration of Risk**

Financial instruments that subject the Association to concentrations of credit risk consist of cash deposits. The Association places its cash deposits with high quality financial institutions. Deposits exceed federally insured limits as of June 30, 2019 and 2018.

**Estimates and Assumptions**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

For the purposes of the statements of cash flows, all highly liquid investments available for use with an initial maturity of three months or less are considered to be cash equivalents.

**Investments**

Investments in marketable equity securities, US Treasury securities, US Federal Agencies, corporate bonds, and certificates of deposit with original maturities greater than 90 days are reported at fair value. Realized and unrealized gains and losses are reflected in the statements of activities as changes in net assets without restrictions unless their use is restricted by a donor or by law.

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Estimated Collectible Assessments**

Estimated collectible assessments represents the running total of replenishment requests to date minus amounts collected to date through the end of the year, and is the amount the Association expects to collect from members. The Association has determined that an allowance for uncollectible amounts is not necessary due to the method used to calculate the balance.

The Association charges interest on late payment of assessments at a monthly rate of 1.5%. Interest is added to the assessment for payments received after the due date of the assessment.

**Dosage Based Assessments**

Funds collected from health insurers and TPAs of health plans in the state of Washington, (including administrative revenue and reserve portion discussed below), are determined using a Dosage Based Assessment methodology. At each vaccine administration of a child in the State of Washington, not otherwise eligible for state or federally-funded vaccine programs, the provider's office charges for and generates a claim for administrative services and also generates an item, resembling a claim form, on which the per-vaccine assessment is reported to the respective payor. The per-vaccine assessment amounts are established periodically by the Association. The payor pays the provider for the administration claim, and also pays the assessment amount to the Association, in a manner similar to payment of a claim for the cost of vaccines. The Association collects these assessments and remits payments to the State of Washington DOH to pay its allocated share of vaccine costs each time a vaccine replenishment order for the State's Universal Childhood Vaccine Program is due. The cost for each vaccine is negotiated by the Center for Communicable Diseases.

**Remittance to Universal Purchase Account**

The Plan of Operation requires the Association to periodically remit its assessment receipts, less the Association's administrative costs and any reserves set by the board or its Finance Committee, to the credit of the universal vaccine purchase account (UVPA) established pursuant to RCW 43.70.720. Funds transferred to the UVPA are to be delivered on a just-in-time basis, in order to support the assessment collection process. The DOH or its designee has access privileges to be able to directly observe the balances in the Association's accounts, and the Association is required to promptly respond to any inquiry of the DOH concerning the availability and timely transfer of funds, enabling the DOH to make payment of the Association's share under the statute for vaccine purchases made by the state of Washington.

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Revenue Recognition**

The Association collects member assessments that are remitted to the DOH for purchase of vaccines. In addition, the Plan of Operation allows the Association to retain sufficient funds to cover its administrative costs, net of investment income. Expense is recognized for the administrative costs of operating the Association. The replenishment of vaccines and collection of vaccine assessments are similar to agency transactions. Although these transactions are not considered revenue or expenses of the Association, they are included in the statements of activities as vaccine replenishments to reflect the gross amount of collections and replenishments.

**Assessments Collected in Excess of Vaccine Funding and Administrative Costs**

The Association has collected assessments in excess of amounts required to be paid to the DOH through the end of the accounting period for childhood vaccine funding and administrative costs. The Association is a limited purpose entity whose funds are dedicated solely to the specific purposes discussed above. These excess assessment collections, which may accumulate from time to time, will be applied to (i) future vaccine funding obligations of the Association, and (ii) reasonable and necessary operating costs of the Association. The Association maintains a level of excess collections (reserves) to be able to meet DOH needs for vaccine purchases and ensure adequate funds for operations. As of June 30, 2019 and 2018, assessments collected in excess of vaccine funding and administrative activities totaled \$62,263,489 and \$44,249,204, respectively.

**Functional Allocation of Expenses**

The costs of providing the various programs and other activities have been summarized on a functional basis in the statements of activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Vaccine replenishments are considered to be program expenses and all other expenses are administrative.

**Income Taxes**

The Association follows Financial Accounting Standards Board (FASB) *Accounting Standards Codification (ASC) Topic 740, Income Taxes (Topic 740)*. Topic 740 clarifies the accounting for uncertainty in income taxes.

The Association operates as a tax-exempt organization created by Washington State statute and as an affiliate of a governmental unit. In order to obtain 501(c)(3) status and to determine whether filing of an annual federal information return (Form 990) is required, the Association prepared and submitted Form 1023 to the Internal Revenue Service (IRS) in June 2012. On May 14, 2013, the IRS granted 501(c)(3) tax-exempt status and determined that the filing of Form 990 is not required in prior or future years.

Management evaluated the Association's tax positions and concluded that the Association had taken no uncertain tax positions that require adjustments to the financial statements. Based upon its evaluation, the Association has concluded that it is operating in compliance within its tax-exempt status and that there are no matters that would create taxable income.

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 2 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**Reclassifications**

Certain reclassifications have been made to the 2018 financial statements in order to conform with the 2019 presentation with no effect on previously reported changes in net assets.

**Subsequent Events**

The board of directors and management has evaluated subsequent events through REPORT DATE, the date the financial statements were available to be issued.

**NOTE 3 INVESTMENTS AND FAIR VALUE MEASUREMENTS**

The FASB established a framework for measuring fair value and disclosing fair value measurements to financial statement users. Fair value is the price that would be received to sell an asset or paid to transfer a liability (referred to as the exit price) in an orderly transaction between market participants in the principal market, or if none exists, the most advantageous market, for specific assets or liabilities at the measurement dates. The fair value should be based on assumptions that market participants would use, including consideration of nonperformance risk.

In determining fair value, the Association uses various valuation approaches. The FASB established a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Association. Unobservable inputs are inputs that reflect the Association's assumptions that market participants would use in pricing the assets or liabilities developed based on the best information available in the circumstances.

The hierarchy is broken down into three levels based on the observability of inputs as follows:

*Level 1* – Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets to which the Association has access.

*Level 2* – Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in inactive markets; inputs other than quoted market prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability.

*Level 3* – Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 3 INVESTMENTS AND FAIR VALUE MEASUREMENTS (CONTINUED)**

The availability of observable inputs can vary and is affected by a wide variety of factors, including, for example, the type of asset or liability, the liquidity of markets, and other characteristics particular to the transaction. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Association in determining fair value is greatest for instruments categorized in Level 3.

In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety is determined based on the lowest level input that is significant to the fair value measurement in its entirety.

Fair value is a market-based measure considered from the perspective of a market participant rather than an organization-specific measure. Therefore, even when market assumptions are not readily available, the Association's own assumptions are set to reflect those that the Association believes market participants would use in pricing the asset or liability at the measurement date.

The following table sets for the by level, within the fair value hierarchy, the Association's assets at fair value as of June 30, 2019:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Money Market Funds	\$ 608,172	\$ -	\$ -	608,172
Mutual Funds	5,563,317	-	-	5,563,317
Corporate Bonds	-	18,645,662	-	18,645,662
US Treasuries	-	6,050,560	-	6,050,560
US Federal Agencies	-	4,489,157	-	4,489,157
Certificates of Deposit	-	10,199,108	-	10,199,108
Total Schedule of Investments	<u>\$ 6,171,489</u>	<u>\$ 39,384,487</u>	<u>\$ -</u>	<u>\$ 45,555,976</u>

The following table sets for the by level, within the fair value hierarchy, the Association's assets at fair value as June 30, 2018:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Money Market Funds	<u>\$ 9,118</u>	<u>\$ -</u>	<u>\$ -</u>	<u>\$ 9,118</u>

**WASHINGTON VACCINE ASSOCIATION  
NOTES TO FINANCIAL STATEMENTS  
JUNE 30, 2019 AND 2018**

**NOTE 4 INFORMATION REGARDING LIQUIDITY AND AVAILABILITY**

The Association is substantially supported by assessment income. As part of the Association's liquidity management, it has a policy to structure its financial assets to be available for its general expenditures, liabilities, and other obligations come due. Financial assets in excess of near-term cash requirements are invested in various marketable securities.

The Board of Directors of the Association (Board) has determined that to carry out its statutory and charitable purpose, the Association should maintain minimum reserves in amounts projected by the Board to cover several months of vaccines costs plus the next flu season vaccines to provide liquidity to fund the costs of such vaccines through timely (just in time) deposits to the State's universal vaccine purchase account.

The following table reflects the Association's financial assets available within one year to meet cash needs for general expenditures as of June 30:

	<u>2019</u>	<u>2018</u>
Cash and Cash Equivalents	\$ 4,921,995	\$ 34,120,976
Estimated Collectible Assessments	5,345,981	6,355,445
Investments	<u>45,555,976</u>	<u>9,118</u>
Total Financial Assets Available to Meet Cash		
Needs for General Expenditures Within One Year	<u>\$ 55,823,952</u>	<u>\$ 40,485,539</u>

**NOTE 5 REMITTANCE TO THE STATE OF WASHINGTON**

Pursuant to the Association's statutory purposes, transfers of \$65,740,161 and \$64,339,330 were made by the Association to the state of Washington's UVPA during the years ended June 30, 2019 and 2018, respectively.

**NOTE 6 CONTINGENCIES**

There is an inherent risk that a certain portion of the vaccines purchased by the DOH will not be administered to children, resulting in vaccine shrinkage. If member assessments are insufficient for reimbursement to the DOH for purchases of vaccines, the Association would be liable to the DOH to cover the shortfall through reserves. The Association's reserves are intended to meet any such contingency.

September 19, 2019 WVA Finance/Audit Committee Meeting  
Proposed Form of Votes

The following are suggested forms of votes only. They are intended to be an aid to facilitate work by individual directors. All board policy and the final form of votes is exclusively the province of the Board acting collectively as a Board of Directors.

Item under Agenda Section 2:

VOTED: To approve May 23, 2019 Finance Committee meeting minutes.

[To approve May 23, 2019 Finance Committee meeting minutes with the changes suggested at the meeting.]

Item under Agenda Section 3:

VOTED: To approve publication of the 2018/19 audited financial statements and independent auditor's report.

[To approve publication of the 2018/19 audited financial statements and independent auditor's report with the changes suggested at the meeting.]

## Seattle-Tacoma International Airport, WA

- **Depart from Seattle-Tacoma International Airport, WA**

-  518

- 1.9 mi

- Take ramp right for WA-518 East toward Tacoma / Seattle

- 1.5 mi

- Take ramp left for I-5 North toward Seattle

-  5

- 0.6 mi

- Keep straight onto I-5 N

- 10.6 mi

- At exit 165, take ramp left and follow signs for Seneca St.

- 0.3 mi

- Bear left onto Seneca St

- 338 ft

- Turn left onto 5th Ave

- 0.3 mi

- Arrive at 701 5th Ave Ste 4900, Seattle, WA 98104

- The last intersection is Columbia St If you reach Cherry St, you've gone too far

- Cigna - Columbia Tower: 701 5th Ave Ste 4900, Seattle, WA 98104

- (206) 564-8945

## the north (on I-5 S)

-  5

- Depart I-5 S toward I-5 Express Ln

- 2.7 mi

- At exit 165A, take ramp right for 6th Ave toward James St.

- 0.4 mi

- Turn right onto Columbia St

- 327 ft

- Turn left onto 5th Ave

- 269 ft

- Arrive at 701 5th Ave Ste 4900, Seattle, WA 98104

- The last intersection is Columbia St If you reach Cherry St, you've gone too far

- Cigna - Columbia Tower: 701 5th Ave Ste 4900, Seattle, WA 98104

- (206) 564-8945



**the south (on I-5 N)**

- Depart I-5 N toward I-5 Express Ln
- 1.5 mi  
At exit 165, take ramp left and follow signs for Seneca St.
- 0.3 mi  
Bear left onto Seneca St
- 338 ft  
Turn left onto 5th Ave
- 0.3 mi  
Arrive at 701 5th Ave Ste 4900, Seattle, WA 98104  
The last intersection is Columbia St If you reach Cherry St, you've gone too far  
Cigna - Columbia Tower: 701 5th Ave Ste 4900, Seattle, WA 98104  
(206) 564-8945

**the east (on I-90 W)**

- Depart I-90 W toward I-90 Bus Ln
- 0.6 mi  
At exit 2C, take ramp right for I-5 North toward Madison St / Convention Center
- 1.2 mi  
Turn left onto Madison St
- 0.1 mi  
Turn left onto 5th Ave
- 0.2 mi  
Arrive at 701 5th Ave Ste 4900, Seattle, WA 98104  
The last intersection is Columbia St If you reach Cherry St, you've gone too far  
Cigna - Columbia Tower: 701 5th Ave Ste 4900, Seattle, WA 98104  
(206) 564-8945

**the east (on WA-520 W)**

- Depart WA-520 W
- 0.6 mi  
Take ramp left for I-5 South toward Portland
- 2.5 mi  
At exit 165A, take ramp right for 6th Ave toward James St.
- 0.4 mi  
Turn right onto Columbia St
- 327 ft  
Turn left onto 5th Ave
- 269 ft  
Arrive at 701 5th Ave Ste 4900, Seattle, WA 98104  
The last intersection is Columbia St If you reach Cherry St, you've gone too far  
Columbia Tower Club: 701 5th Ave Ste 4900, Seattle, WA 98104  
(206) 564-8945